Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Braz. j. infect. dis ; 15(5): 413-419, Sept.-Oct. 2011. ilus, tab
Artigo em Inglês | LILACS | ID: lil-612698

RESUMO

OBJECTIVES: This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity. METHODS: The isolates studied were obtained from the COMPACT-COLOMBIA surveillance program conducted between February and November 2009. Antimicrobial susceptibility testing was conducted by broth microdilution method according to the CLSI guidelines. Doripenem, imipenem-cilastatin, and meropenem, were the modeled antibiotics. A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets were defined as free drug concentrations above the MIC for at least 40 percent of the dosing interval. RESULTS: All carbapenem regimens obtained optimal exposures against E. coli, unlike the other Enterobacteriaceae tested. Against P. aeruginosa, only a prolonged infusion of doripenem exceeded the 90 percent cumulative fraction of response (CFR) threshold. Worrisomely, no regimens for any of the drugs tested obtained optimal CFR against A. baumannii. For P. aeruginosa intensive care unit (ICU) isolates, CFR was approximately 20 percent lower for isolates collected in the respiratory tract compared with bloodstream or intra-abdominal for imipenem and meropenem. Noteworthy, all doripenem and meropenem regimens achieved greater than 90 percent CFR against bloodstream and respiratory isolates of K. pneumoniae. CONCLUSIONS: Our data suggests that higher dosing and prolonged infusion of doripenem or meropenem may be suitable for empirically treating ICU P. aeruginosa, while none of the carbapenems achieved optimal cumulative fraction of response against A. baumannii. Standard dosing regimens of all the carbapenems tested achieved optimal CFR against E. coli isolates, but higher carbapenem dosages might be required for empiric treatment of K. pneumoniae, particularly from an intra-abdominal source. Non-standard dosage regimens studied in this modeling should be proven effective in prospective clinical trials.


Assuntos
Humanos , Antibacterianos/farmacologia , Carbapenêmicos/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Imipenem/farmacologia , Tienamicinas/farmacologia , Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacocinética , Colômbia , Carbapenêmicos/farmacocinética , Escherichia coli/efeitos dos fármacos , Bactérias Gram-Negativas/metabolismo , Infecções por Bactérias Gram-Negativas/metabolismo , Infecções por Bactérias Gram-Negativas/microbiologia , Infusões Intravenosas , Unidades de Terapia Intensiva , Imipenem/farmacocinética , Klebsiella pneumoniae/efeitos dos fármacos , Método de Monte Carlo , Testes de Sensibilidade Microbiana/métodos , Pseudomonas aeruginosa/efeitos dos fármacos , Tienamicinas/farmacocinética
2.
Braz J Infect Dis ; 15(5): 413-9, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22230846

RESUMO

OBJECTIVES: This study was designed to simulate standard and optimized dosing regimens for intravenous antibiotics against contemporary populations of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa using MIC distribution data to determine which of the tested carbapenem regimens provided the greatest opportunity for obtaining maximal pharmacodynamic (PD) activity. METHODS: The isolates studied were obtained from the COMPACT-COLOMBIA surveillance program conducted between February and November 2009. Antimicrobial susceptibility testing was conducted by broth microdilution method according to the CLSI guidelines. Doripenem, imipenem-cilastatin, and meropenem, were the modeled antibiotics. A 5,000 patient Monte Carlo simulation was performed for each regimen and PD targets were defined as free drug concentrations above the MIC for at least 40% of the dosing interval. RESULTS: All carbapenem regimens obtained optimal exposures against E. coli, unlike the other Enterobacteriaceae tested. Against P. aeruginosa, only a prolonged infusion of doripenem exceeded the 90% cumulative fraction of response (CFR) threshold. Worrisomely, no regimens for any of the drugs tested obtained optimal CFR against A. baumannii. For P. aeruginosa intensive care unit (ICU) isolates, CFR was approximately 20% lower for isolates collected in the respiratory tract compared with bloodstream or intra-abdominal for imipenem and meropenem. Noteworthy, all doripenem and meropenem regimens achieved greater than 90% CFR against bloodstream and respiratory isolates of K. pneumoniae. CONCLUSIONS: Our data suggests that higher dosing and prolonged infusion of doripenem or meropenem may be suitable for empirically treating ICU P. aeruginosa, while none of the carbapenems achieved optimal cumulative fraction of response against A. baumannii. Standard dosing regimens of all the carbapenems tested achieved optimal CFR against E. coli isolates, but higher carbapenem dosages might be required for empiric treatment of K. pneumoniae, particularly from an intra-abdominal source. Non-standard dosage regimens studied in this modeling should be proven effective in prospective clinical trials.


Assuntos
Antibacterianos/farmacologia , Carbapenêmicos/farmacologia , Bactérias Gram-Negativas/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Imipenem/farmacologia , Tienamicinas/farmacologia , Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos/farmacocinética , Carbapenêmicos/farmacocinética , Colômbia , Doripenem , Escherichia coli/efeitos dos fármacos , Bactérias Gram-Negativas/metabolismo , Infecções por Bactérias Gram-Negativas/metabolismo , Infecções por Bactérias Gram-Negativas/microbiologia , Humanos , Imipenem/farmacocinética , Infusões Intravenosas , Unidades de Terapia Intensiva , Klebsiella pneumoniae/efeitos dos fármacos , Meropeném , Testes de Sensibilidade Microbiana/métodos , Método de Monte Carlo , Pseudomonas aeruginosa/efeitos dos fármacos , Tienamicinas/farmacocinética
3.
Biomédica (Bogotá) ; 30(3): 371-381, sept. 2010. tab, graf
Artigo em Espanhol | LILACS | ID: lil-616869

RESUMO

Introducción. La resistencia a antimicrobianos se ha identificado como uno de los mayores problemas de salud pública, por lo cual debe ser vigilada permanentemente a través de sistemas efectivos de vigilancia. Objetivo. Describir el comportamiento de la resistencia antimicrobiana de bacilos Gram negativos, en las instituciones hospitalarias pertenecientes al Grupo para el Estudio de la Resistencia Nosocomial en Colombia, de enero 2006 a diciembre 2008. Materiales y métodos. Es un estudio descriptivo realizado con la información de los perfiles de sensibilidad bacteriana suministrada por 14 hospitales de tercer nivel en siete ciudades de Colombia, definidos como el Grupo para el Estudio de la Resistencia Nosocomial en Colombia, de enero de 2006 a diciembre de 2008. Usando el software WHONET 5.4, se describe el comportamiento de la resistencia bacteriana de las especies de Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae y Enterobacter cloacae) y bacilos Gram negativos no fermentadores (Pseudomonas aeruginosa y Acinetobacter baumannii) frente a antibióticos seleccionados como marcadores de resistencia en salas generales y unidades de cuidados intensivos de pacientes adultos.Resultados. En algunas Enterobacteriaceae se observó disminución de la frecuencia de resistencia antimicrobiana, mientras que P. aeruginosa se consolida como un germen multirresistente, cuyas frecuencias de resistencia continúan en aumento. Conclusiones. Los programas de vigilancia pueden tener un impacto en la disminución significativa de gérmenes multirresistentes, ya que contribuyen a la adecuada implementación de protocolos encaminados a fortalecer las estrategias de control de infecciones y el manejo racional de antibióticos en cada hospital.


Introduction. Antimicrobial resistance has been identified as one of the major public health problems worldwide. To facilitate its control, bacterial resistance levels must be monitored permanently by effective surveillance systems.Objective. To describe the antimicrobial resistance patterns of Gram negative bacilli in Colombian hospitals over a 3-year period. Materials and methods. This descriptive study used the bacterial susceptibility profiles provided by 14 tertiary-care hospitals belonging to the Colombian Nosocomial Resistance Study Group. The hospitals were located in 7 major cities in Colombia, and provided records over the period January 2006 to December 2008. Using WHONET 5.4, the antimicrobial resistance patterns were described for the Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae) and non-fermenters (Pseudomonas aeruginosa and Acinetobacter baumannii). Comparisons were made in the bacterial responses to selected antibiotics in samples from general wards and from adult intensive care units. Results. The antimicrobial resistance frequencies of several Enterobacteriaceae species showed a decreasing trend. In contrast, P. aeruginosa was demonstrated to be a multidrug-resistance organism with increasing resistance frequencies.Conclusions. These data emphasize the importance of surveillance programs in detecting presence of multidrug-resistant organisms. This information will aid the implementation of protocols aimed to strengthen the infection control strategies and antibiotic stewardship in each hospital.


Assuntos
Humanos , Bactérias , Farmacorresistência Bacteriana
4.
Expert Rev Anti Infect Ther ; 8(3): 303-15, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20192684

RESUMO

Multidrug-resistant nonfermenters are a worldwide threat. Pseudomonas aeruginosa and Acinetobacter baumannii have been associated with high mortality and treatment failures. In addition, therapeutic options are increasingly narrowed, mainly due to widespread resistance in these pathogens and a shortage of new antimicrobial compounds. Hence, old, potent but toxic antibiotics such as the polymyxins are re-emerging as therapeutic options. Maximizing pharmacokinetics/pharmacodynamics with existing agents is also a worthwhile approach to explore. This problem exemplifies the critical need for new drug development for multidrug-resistant Gram-negative microorganisms.


Assuntos
Infecções por Acinetobacter/tratamento farmacológico , Acinetobacter baumannii/efeitos dos fármacos , Antibacterianos , Farmacorresistência Bacteriana Múltipla/efeitos dos fármacos , Infecções por Pseudomonas/microbiologia , Pseudomonas aeruginosa/efeitos dos fármacos , Infecções por Acinetobacter/microbiologia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Quimioterapia Combinada , Humanos , Testes de Sensibilidade Microbiana , Polimixinas/farmacologia , Polimixinas/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico
5.
Biomedica ; 30(3): 371-81, 2010.
Artigo em Espanhol | MEDLINE | ID: mdl-21713339

RESUMO

INTRODUCTION: Antimicrobial resistance has been identified as one of the major public health problems worldwide. To facilitate its control, bacterial resistance levels must be monitored permanently by effective surveillance systems. OBJECTIVE: To describe the antimicrobial resistance patterns of Gram negative bacilli in Colombian hospitals over a 3-year period. MATERIALS AND METHODS: This descriptive study used the bacterial susceptibility profiles provided by 14 tertiary-care hospitals belonging to the Colombian Nosocomial Resistance Study Group. The hospitals were located in 7 major cities in Colombia, and provided records over the period January 2006 to December 2008. Using WHONET 5.4, the antimicrobial resistance patterns were described for the Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae and Enterobacter cloacae) and non-fermenters (Pseudomonas aeruginosa and Acinetobacter baumannii). Comparisons were made in the bacterial responses to selected antibiotics in samples from general wards and from adult intensive care units. RESULTS: The antimicrobial resistance frequencies of several Enterobacteriaceae species showed a decreasing trend. In contrast, P. aeruginosa was demonstrated to be a multidrug-resistance organism with increasing resistance frequencies. CONCLUSIONS: These data emphasize the importance of surveillance programs in detecting presence of multidrug-resistant organisms. This information will aid the implementation of protocols aimed to strengthen the infection control strategies and antibiotic stewardship in each hospital.


Assuntos
Antibacterianos/farmacologia , Infecções Bacterianas/microbiologia , Infecção Hospitalar/microbiologia , Farmacorresistência Bacteriana , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Negativas/patogenicidade , Hospitais , Adulto , Antibacterianos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Infecções Bacterianas/prevenção & controle , Colômbia , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/prevenção & controle , Bactérias Gram-Negativas/isolamento & purificação , Humanos , Programas de Rastreamento , Testes de Sensibilidade Microbiana
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...